Page 1 of 5Free preview · 1–5

About this document

Healthcare provider fact sheet dated December 23, 2022, for the SCoV-2 Ag Detect™ Rapid Test, marked “REVOKED.” Describes emergency-use testing of anterior nasal swab specimens for SARS-CoV-2 antigens, eligible testing settings, interpretation of positive and negative results, false-result risks, and serial testing recommendations. Also explains Emergency Use Authorization, available alternatives, adverse-event reporting, and CDC, FDA, and manufacturer information resources. Negative results are presumptive and do not rule out COVID-19.

Free preview text

The first 5 pages, shown as text so search engines and readers can find this document.

Page 1

COVID-19 FACT SHEET FOR HEALTHCARE PROVIDERS SCOV-2 AG DETECT™ RAPID TEST InBios International, Inc. December 23, 2022 All individuals whose specimens are tested with this product will receive the Fact Sheet for Patients for the product. This Fact Sheet informs you of the significant known and potential risks and benefits of the emergency use of the SCoV-2 Ag Detect™ Rapid Test. WHERE CAN I GO FOR GENERAL INFORMATION ON COVID-19? For general information on COVID-19, including the symptoms of COVID-19, infection control precautions, and other information please check the CDC COVID-19 webpage (see links provided in “Where can I go for updates and more information?” section at the end of this document) or your local jurisdiction’s website for the most up to date information. WHAT DO I NEED TO KNOW ABOUT COVID-19 TESTING WITH THIS PRODUCT? • The SCoV-2 Ag DetectTM Rapid Test can be used to test direct anterior nasal swab specimens immediately after collection. • The SCoV-2 Ag DetectTM Rapid Test should be ordered for the detection of SARS-CoV-2 antigens by a healthcare provider. • The SCoV-2 Ag DetectTM Rapid Test is authorized for individuals who are suspected of COVID-19 by their healthcare provider within the first 5 days of symptom onset when tested at least twice over three days with at least 48 hours between tests and from individuals without symptoms or other epidemiological reasons to suspect COVID-19 when tested at least three times over five days with at least 48 hours between tests. • The SCoV-2 Ag DetectTM Rapid Test is authorized for use in laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, that meet requirements to perform moderate, high or waived complexity tests. • The SCoV-2 Ag DetectTM Rapid Test is authorized for use at the Point of Care (POC), i.e., in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation. • Please refer to the SCoV-2 Ag DetectTM Rapid Test Instructions for Use for additional information. • There is a higher chance of false negative results with antigen tests than with laboratory- based molecular tests due to the lower sensitivity of the test technology. This means that there is a higher chance this test will give a false negative result in an individual with COVID-19 as compared to a molecular test, especially in samples with low viral load. Specimens should be collected with appropriate infection control precautions. When collecting and handling specimens from individuals suspected of being infected with the virus that causes COVID-19, appropriate personal protective equipment should be used as outlined in the CDC Interim Laboratory Biosafety Guidelines for Handling and Processing Specimens Associated with Coronavirus Disease 2019 (COVID-19). For additional information, refer to CDC Interim Guidelines for Collecting, Handling, and Testing Clinical Specimens from Persons Under Investigation (PUIs) for Coronavirus Disease 2019 (COVID-19).REVOKED

Page 2

2 | P a g e WHAT DOES IT MEAN IF THE SPECIMEN TESTS POSITIVE FOR THE VIRUS THAT CAUSES COVID-19? A positive test result for COVID-19 indicates that antigens from SARS-CoV-2 were detected, and therefore the individual being tested is infected with the virus and presumed to be contagious. Laboratory test results should always be considered in the context of clinical observations and epidemiological data (such as local prevalence rates and current outbreak/epicenter locations) in determining individual diagnosis and patient management decisions and should follow current CDC guidelines. The SCoV-2 Ag DetectTM Rapid Test has been designed to minimize the likelihood of false positive test results. However, in the event of a false positive result, risks could include the following: a needless recommendation for the patient to isolate that might limit contact with family or friends and the ability to work, delayed diagnosis and treatment for the true infection causing the patient’s symptoms, potentially increased likelihood that the patient could contract COVID-19 from other potentially COVID-19 positive patients isolated in the same areas, unnecessary prescription of a treatment or therapy, needless monitoring of close contacts for symptoms, or other unintended adverse effects. All laboratories using this test must follow the standard testing and reporting guidelines according to their appropriate public health authorities. WHAT DOES IT MEAN IF THE SPECIMEN TESTS NEGATIVE FOR THE VIRUS THAT CAUSES COVID-19? A negative serial test result for this test means that SARS-CoV-2 antigens was not present in the specimen above the limit of detection. All negative results are presumptive and confirmation with a molecular assay, if necessary for patient management, may be performed. However, a negative result does not rule out COVID-19 and should not be used as the sole basis for treatment or patient management decisions, including infection control decisions (such as discontinuation of isolation precautions). Antigen tests are known to be less sensitive than molecular tests that detect viral nucleic acids. The amount of antigen in a sample may decrease as the duration of illness increases. Specimens collected after day five (5) of illness may be more likely to be negative compared to a RT-PCR assay. Therefore, negative results from patients with symptom onset beyond five (5) days should be treated as presumptive and confirmed with a molecular assay, if necessary, for patient management. It is possible to test a person too early or too late during SARS-CoV-2 infection to make an accurate diagnosis via the SCoV-2 Ag DetectTM Rapid Test. When diagnostic testing is negative, the possibility of a false negative result should be considered in the context of an individual’s recent exposures and the presence of clinical signs and symptoms consistent with COVID-19. The possibility of a false negative result should especially be considered if the individual’s recent exposures or clinical presentation indicate that COVID-19 is likely, and diagnostic tests for other causes of illness (e.g., other respiratory illness) are negative. If COVID-19 is still suspected based on exposure history together with other clinicalREVOKED

Page 3

3 | P a g e findings, re-testing or testing with molecular methods should be considered by healthcare providers in consultation with public health authorities. Additional testing may be helpful to ensure testing was not conducted too early. Risks to a patient of a false negative test result include delayed or lack of supportive treatment, lack of monitoring of infected individuals and their household or other close contacts for symptoms resulting in increased risk of COVID-19 spread within the community, or other unintended adverse events. For additional recommendations regarding infection control, refer to CDC’s Discontinuation of Isolation for Persons with COVID-19 Not in Healthcare Settings (Interim Guidance) (see links provided in “Where can I go for updates and more information?” section). The performance of this test was established based on the evaluation of a limited number of clinical specimens collected between February 2021 to April 2021. The clinical performance has not been established in all circulating variants but is anticipated to be reflective of the prevalent variants in circulation at the time and location of the clinical evaluation. Performance at the time of testing may vary depending on the variants circulating, including newly emerging strains of SARS-CoV-2 and their prevalence, which change over time. WHAT DO I NEED TO KNOW ABOUT SERIAL TESTING? Serial testing of individuals whose initial test result is negative assists in identifying infected individuals earlier and facilitate timely infection control practices. A negative test result does not rule out infection but repeat testing over three days for symptomatic individuals or five days for asymptomatic individuals with at least 48 hours between tests may decrease the risks of false negative results. An initial negative test result should be the first of a minimum of two tests. An asymptomatic individual undergoing serial testing who obtained two or more negative test results may require ongoing serial testing or confirmatory testing, depending on patient history and potential exposures. An asymptomatic individual undergoing serial testing who obtained one or more positive results indicates that SARS-CoV-2 antigen is present in the patient’s sample but does not rule out coinfection with other pathogens. For additional recommendations regarding confirmation of antigen test results, please refer to the CDC’s Interim Guidance for Antigen Testing for SARS-CoV-2 (see links provided in “Where can I go for updates and more information” section). WHAT IS AN EUA? The U.S. FDA has made this test available under an emergency access mechanism called an Emergency Use Authorization (EUA). The EUA is supported by the Secretary of Health and Human Service’s (HHS’s) declaration that circumstances exist to justify the emergency use of in vitro diagnostics (IVDs) for the detection and/or diagnosis of the virus that causes COVID-19. An IVD made available under an EUA has not undergone the same type of review as an FDA- approved or cleared IVD. FDA may issue an EUA when certain criteria are met, which includes that there are no adequate, approved, available alternatives, and based on the totality of scientificREVOKED

Page 4

4 | P a g e evidence available, it is reasonable to believe that this IVD may be effective in diagnosing COVID-19. The EUA for this test is in effect for the duration of the COVID-19 declaration justifying emergency use of IVDs, unless the declaration is terminated or authorization is revoked sooner. WHAT ARE THE APPROVED AVAILABLE ALTERNATIVES? Any tests that have received full marketing status (e.g., cleared, approved), as opposed to an EUA, by FDA can be found by searching the medical device databases here: https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory- assistance/medical-device-databases. A cleared or approved test should be used instead of a test made available under an EUA, when appropriate and available. FDA has issued EUAs for other tests that can be found at: https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy- framework/emergency-use-authorization. WHERE DO I REPORT ADVERSE EVENTS? Report Adverse events, including problems with test performance or results, to MedWatch by submitting the online FDA Form 3500 (https://www.accessdata.fda.gov/scripts/medwatch/index.cfm?action=reporting.home) or by calling 1-800-FDA-1088 WHERE CAN I GO FOR UPDATES AND MORE INFORMATION? CDC WEBPAGES: General: https://www.cdc.gov/coronavirus/2019-ncov/index.html Symptoms: https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html Healthcare Professionals: https://www.cdc.gov/coronavirus/2019-nCoV/hcp/index.html Information for Laboratories: https://www.cdc.gov/coronavirus/2019-nCoV/lab/index.html Laboratory Biosafety: https://www.cdc.gov/coronavirus/2019-nCoV/lab/lab-biosafety-guidelines.html Isolation Precautions in Healthcare Settings: https://www.cdc.gov/infectioncontrol/guidelines/isolation/index.html Specimen Collection: https://www.cdc.gov/coronavirus/2019-nCoV/lab/guidelines-clinical-specimens.html Infection Control: https://www.cdc.gov/coronavirus/2019-ncov/php/infection-control.html Discontinuation of Isolation: https://www.cdc.gov/coronavirus/2019-ncov/hcp/disposition-in-home-patients.html FDA WEBPAGES: General: www.fda.gov/novelcoronavirus EUAs: (includes links to patient fact sheet and manufacturer’s instructions) https://www.fda.gov/medical- devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/in-vitro-diagnostics-euas InBios International, Inc.: 307 Westlake Ave. N., Suite 300 Seattle, WA 98109 USAREVOKED

Page 5

5 | P a g e Customer and Technical Support: Telephone: 206-344-5821 Fax: 206-344-5823 Website: www.inbios.com Email: inquiries@inbios.comREVOKED

Tags

Doxxly editorial guide

COVID-19 Fact Sheet for Healthcare Providers: SCoV-2 Ag Detect™ Rapid Test: summary, contents and background

This guide helps you understand the scope of COVID-19 Fact Sheet for Healthcare Providers: SCoV-2 Ag Detect™ Rapid Test before or alongside reading the original document. It is based on the catalogue record, credited creator, source, classification and topics shown on this page. It does not replace the original work and does not invent claims about passages that Doxxly cannot verify.

Summary and overview

COVID-19 Fact Sheet for Healthcare Providers: SCoV-2 Ag Detect™ Rapid Test is a 5-page documentcredited to Dara K. Hollis. Healthcare provider fact sheet dated December 23, 2022, for the SCoV-2 Ag Detect™ Rapid Test, marked “REVOKED.” Describes emergency-use testing of anterior nasal swab specimens for SARS-CoV-2 antigens, eligible testing settings, interpretation of positive and negative results, false-result risks, and serial testing recommendations. Also explains Emergency Use Authorization, available alternatives, adverse-event reporting, and CDC, FDA, and manufacturer information resources. Negative results are presumptive and do not rule out COVID-19. It appears in the Medicine & Wellbeing collection, which groups it with other material that readers may use for comparison and further study.

The item can be approached in several ways. A reader looking for a quick orientation can begin with the free five-page preview, inspect the page structure and use the metadata to judge relevance. Someone undertaking deeper research can work through the complete file, search its indexed text, record useful page references and compare its treatment of COVID-19, SARS-CoV-2, Rapid antigen testing, Healthcare provider fact sheet, Serial testing, Emergency Use Authorization, Revoked, InBios with the related resources linked below.

Rather than reducing the work to a single claim, this page treats it as a source that should be read in context. The title, creator, publication source, licence and format all help explain what kind of evidence it may offer. Readers should distinguish the original author's statements from Doxxly's catalogue description, and should cite the original edition when using the material in academic, professional or published work.

Key topics and reader takeaways

The catalogue connects this document with COVID-19, SARS-CoV-2, Rapid antigen testing, Healthcare provider fact sheet, Serial testing, Emergency Use Authorization, Revoked, InBios. These terms offer practical entry points rather than a substitute for close reading. Start by identifying the definitions, examples, arguments, tables or visual explanations attached to each topic. Then note where the creator draws connections, makes distinctions or moves from background material to a conclusion, recommendation, calculation or narrative development.

A useful reading method is to separate description from interpretation. First record what the item actually presents: names, headings, figures, formulas, quotations or stated propositions. Next consider why those details matter within the whole work. Finally compare them with another source from the same subject area. This process helps turn a long digital file into evidence that can be evaluated rather than merely skimmed.

Table of contents and reading guide

The following is an editorial content guide based on the verified catalogue topics. It is not represented as the original author's formal table of contents. Use it to organise notes while moving through the 5 pages in the player.

  1. Part 1

    COVID-19

    Use this section of the reading guide to identify how COVID-19 appears in COVID-19 Fact Sheet for Healthcare Providers: SCoV-2 Ag Detect™ Rapid Test, note important terms, and connect the subject to the wider purpose of the work.

  2. Part 2

    SARS-CoV-2

    Use this section of the reading guide to identify how SARS-CoV-2 appears in COVID-19 Fact Sheet for Healthcare Providers: SCoV-2 Ag Detect™ Rapid Test, note important terms, and connect the subject to the wider purpose of the work.

  3. Part 3

    Rapid antigen testing

    Use this section of the reading guide to identify how Rapid antigen testing appears in COVID-19 Fact Sheet for Healthcare Providers: SCoV-2 Ag Detect™ Rapid Test, note important terms, and connect the subject to the wider purpose of the work.

  4. Part 4

    Healthcare provider fact sheet

    Use this section of the reading guide to identify how Healthcare provider fact sheet appears in COVID-19 Fact Sheet for Healthcare Providers: SCoV-2 Ag Detect™ Rapid Test, note important terms, and connect the subject to the wider purpose of the work.

  5. Part 5

    Serial testing

    Use this section of the reading guide to identify how Serial testing appears in COVID-19 Fact Sheet for Healthcare Providers: SCoV-2 Ag Detect™ Rapid Test, note important terms, and connect the subject to the wider purpose of the work.

  6. Part 6

    Emergency Use Authorization

    Use this section of the reading guide to identify how Emergency Use Authorization appears in COVID-19 Fact Sheet for Healthcare Providers: SCoV-2 Ag Detect™ Rapid Test, note important terms, and connect the subject to the wider purpose of the work.

  7. Part 7

    Revoked

    Use this section of the reading guide to identify how Revoked appears in COVID-19 Fact Sheet for Healthcare Providers: SCoV-2 Ag Detect™ Rapid Test, note important terms, and connect the subject to the wider purpose of the work.

  8. Part 8

    InBios

    Use this section of the reading guide to identify how InBios appears in COVID-19 Fact Sheet for Healthcare Providers: SCoV-2 Ag Detect™ Rapid Test, note important terms, and connect the subject to the wider purpose of the work.

When a heading in the original differs from this guide, follow the original heading in your citation. Page numbers can also vary between editions. Doxxly's direct page field is useful for navigation, but formal references should include the title, creator, source and edition details available in the file itself.

About Dara K. Hollis

Doxxly credits Dara K. Hollis as the author or creator of COVID-19 Fact Sheet for Healthcare Providers: SCoV-2 Ag Detect™ Rapid Test. This page does not add an unverified biography, job title or institutional affiliation. The attribution is preserved so readers can distinguish the creator from the hosting library and follow the original record when an external author link is available.

Author context matters because a work reflects a particular purpose, audience and point of view. Before relying on the material, consider what the creator set out to explain, when the source was produced and whether later research or revised guidance should also be consulted. For literature and philosophy, compare translations and editions; for technical material, check whether a newer version has superseded the one shown here.

About the source organisation

The recorded source for this item is fda.gov. Doxxly provides access and discovery tools but does not claim to be the original publisher unless explicitly stated. Source links, creator attribution and the recorded Publicly available file collected for editorial review licence are displayed to help readers assess provenance and permitted use.

Provenance is especially important for reports, standards, presentations and working spreadsheets. Check the original source for amendments, supporting files and current policy. A trustworthy research workflow keeps the source URL with any notes or downloaded copy, verifies important figures against the original, and avoids treating an archived document as automatically current.

Visit fda.gov

How to read and use this document

Begin with the title and opening pages, then use the guide above to decide whether to read sequentially or move to a particular topic. The Doxxly player provides previous and next navigation, a direct page field, zoom steps, fit-to-width and fit-to-page modes, rotation and fullscreen. These controls are useful when a page contains small type, a wide table, an image, a scanned layout or a dense sequence of notes.

The first five pages are open to every visitor. A plan unlocks the complete item and full-document search. Search is best used for distinctive names, technical terms or short phrases; broad words can produce too many possible contexts. When you find a useful passage, read the surrounding pages so that a sentence, chart or formula is not separated from its explanation.

If downloading is enabled, members can obtain the original PDF file. Keep the original format when formulas, slide sequencing, pagination or layout carries meaning. Respect the Publicly available file collected for editorial review terms displayed on this page, and use the rights-report link if you believe the attribution or availability needs review.

Research questions to consider

As you read COVID-19 Fact Sheet for Healthcare Providers: SCoV-2 Ag Detect™ Rapid Test, ask which audience the creator addresses, what problem or idea organises the work, what evidence is presented, and which assumptions remain unstated. Note whether important terms are defined consistently and whether examples represent a broader pattern or a narrow case. For quantitative material, record units, time periods, formulas and data sources. For interpretive material, separate the creator's language from your own summary.

A second set of questions concerns relevance today. Which parts remain durable, which depend on their historical or institutional setting, and what would need confirmation from a newer source? Following the tags and the Medicine & Wellbeing collection can reveal useful comparisons. Agreement between sources can strengthen confidence, while disagreement can point to changing definitions, methods, evidence or priorities.

Finally, decide what you need from the item: background knowledge, a quotation, a worked example, a model, a visual explanation or a starting bibliography. That purpose should guide the depth of reading and the notes you keep. Doxxly helps locate and navigate the source; careful interpretation remains the reader's responsibility.

Explore more Medicine & Wellbeing resources

Frequently asked questions about COVID-19 Fact Sheet for Healthcare Providers: SCoV-2 Ag Detect™ Rapid Test

Practical answers about reading, downloading and understanding this document on Doxxly.

More in Medicine & Wellbeing